More engagement with pharma financial, marketing and supply-chain teams calls for easier access, says the company
    "Channel data"--the information on how product inventories are maintained at wholesalers, retailers and elsewhere--used to be the exclusive purview of trade relations managers at pharma companies. But as the drive toward better market signal sensing, lower inventory levels and better forecasting has been accepted by the pharma industry, these data are of value to more parts of the companies. Through use of electronic data interchange (EDI), it is now possible to get an accurate fix of product movement on a daily basis, at least
    New study identifies a category between branded and generic
    For decades, the pharmaceutical market has divided between branded (innovator) drugs and generics, with the latter now the source of more than 85% of prescriptions in the US, and the former representing over 80% of overall industry revenues. Besides differing on price and on single- or multiple-sourcing, each category has a different approval pathway, with generics able to piggyback on innovator drugs' clinical trial data. Now, says IS Health in a new white paper, there is a "Third Sector" emerging--non-patent-protected chemical entities with distinctive or exclusive routes of administration, product combinations or dosage forms
    Self-styled '156-year-old startup' aims to attract small-to-medium companies with outsourced commercialization services
    Dohmen Life Science Services (DLSS; Milwaukee) took the wraps off a newly structured organization which, says CEO Cynthia LaConte, "is a rethinking of our business, based on a future of entrepreneurially driven pharma companies with high-value, small-market products." At a company-sponsored "Entrepreneurial Summit" held this week in Milwaukee, LaConte outlined the recent history of the firm, going back to when it shed its 100+-year-old wholesaling business, then acquired, in rapid succession in the past several years, businesses that are involved in orphan-drug patient support; medical device distribution;
    The pervasiveness of e-prescribing allows for better analysis of adherence, says NEHI
    An issue brief just published by the Network for Excellence in Health Innovation (NEHI; Boston) highlights both the continuing problem of medication adherence, and how a changing healthcare system--specifically, the prevalence of e-prescribing--provides deeper detail on the problem. It also raises the possibility that, with the appropriate incentives in place, community pharmacy could become a more effective means of addressing non-adherence. As has long been known, patients' adherence to prescribed therapies is poor,
    HDMA's research arm studies biosimilar market dynamics
    Biosimilars market dynamics are already taking shape in Europe, but the contrast between pharmacy benefits and medical benefits, and the effects of commercial insurers, will create a different set of dynamics when more biosimilars enter the US market. That's a preliminary view from the Center for Healthcare Supply Chain Research, the research arm of HDMA, in a newly issued report, "Biosimilars: Lessons from Europe and Strategies for the US." Some background: biosimilars are the biologic compounds meant to replicate the therapeutic action of commercialized biologics,
    Cardinal Health works with Americares, and McKesson with World Vision, to deliver supplies
    One million product items, including masks, gowns, biohazard bags and shoe covers have been provided by Cardinal Health for use in Liberia and Sierra Leone, where current estimates are that as many as 1.4 million residents in the two countries might ultimately be affected. The donation, being handled in multiple shipments, is managed by Americares, Inc. (Stamford CT), which works with many US healthcare products manufacturers to provide emergency relief in the developing world following natural disasters and epidemics like the current Ebola crisis. "As a company with concerns for the health and well-being of people
    Company is part of limited distribution for a Lundbeck neurologic treatment
    Business is looking good at Omnicare Specialty Care Group (SCG), a business unit of the Cincinnati company best known for its pharmaceutical services for long-term, assisted-living and other types of chronic care. SCG has opened a new, 75,000-sq.ft. facility in Louisville, KY, for its RxCrossroads unit, dedicated to brand support for specialty pharmaceuticals--more than doubling the RxCrossroads capacity. The building will house RxCrossroads management, HR, IT functionsas well as employee training. "This expansion comes as a result of the double-digit growth in the Specialty Care Group (SCG) segment, and better positions RxCrossroads to fulfill the evolving long-term needs of our customers," said Amit Jain
    Payer trends dominate near-term outlook
    The IMS Health Institute for Healthcare Informatics has published a white paper, "Harbingers of Change in Healthcare: Implications for the role and use of medicines," that's worth a look. It is a little sketchy on how the 10 items were chosen (the report lists five IMS Health analysts as authors; and that's it), while noting that the list is "not intended to be exhaustive." On the other hand, the items are backed up by up-to-date market data (IMS Health's core service); for example, it notes that Medicare prescriptions for sofosburvir (Gilead Science's Sovaldi) and simeprivir (J&J's Olysio), for hepatitis C, jumped eightfold (to over 105,000 prescriptions
    Regulatory compliance continues to exceed cost as a primary driver
    UPS' seventh global survey of supply chain managers in healthcare products finds a greater consensus of industry goals regarding supply chain management, but a lesser degree of actually following through on those goals. All this is occurring in a context of rapid change, driven by the desire to tap into global markets, adoption of new distribution channels, and the urgency to keep up with expanding regulatory compliance initiatives. "One of the values of this survey is the timeline it establishes for industry issues," notes John Menna, VP for healthcare strategy. "In past years, we've asked about global initiatives and found that 81% of healthcare executives planned
    Pharmaceutical Commerce's latest report finds continued growth in these specialized logistics services
    The 5th edition of the Biopharma Cold Chain Sourcebook analyzes economic, regulatory and technological trends in a vital part of today's industry: the shipment of temperature-controlled products. The just-published report calculates that current (2014) expenditures for commercial shipments will be $8.36 billion, rising to $10.28 billion in 2018. By comparison, last year's Sourcebook estimated the 2013 cold-chain business to be $7.5 billion, rising
Pharmaceutical Commerce
Digital Edition
Current Digital Edition
Read the November/December 2014 Issue now - It's Free!
Tracking systems dominate product introductions
Homi Kapadia was appointed head of the Life Sciences Practice last June. He sat down with Pharmaceutical Commerce this summer to talk about trends in life sciences, new initiatives in Deloitte and his evolving role. Here’s what he had to say.
In the past five years, the role of Master Data Management (MDM) and informatics has dramatically changed the strategic and operational objectives of life sciences organizations  continued >
Service providers are building out a wider range of services to meet drug developers' needs  continued >
More complex products and higher risk are changing the nature of pharmaceutical outsourcing  continued >
As rare diseases have emerged as a market opportunity for pharma over the past several years, industry practices are beginning to stabilize  continued >
The drive for lower costs, safer products  continued >
2014 Cold Chain Directory
Our annual compilation of key vendors and service providers in this vital component of pharmaceutical distribution, together with a preview of the IQPC Cold Chain Forum and more late-breaking news
TrialRx service analyzes and mitigates disclosure risks
  |     |     |     |     |     |  
©2014 Pharmaceutical Commerce. All Rights Reserved.  |  Website managed and designed by Offenberger & White.